Systemic Sclerosis-associated Pulmonary Arterial Hypertension
📧 Sign up to get email alerts when something new happens for Systemic Sclerosis-associated Pulmonary Arterial Hypertension.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension [Phase 2]
An update on a Phase 2 trial of oral Ifetroban for diffuse cutaneous systemic sclerosis and SSc-associated pulmonary arterial hypertension, …
-
CLINICAL_TRIALS trial_result · 2026-01-21Clinical Trial Update: Efficacy and Safety of Riociguat in Incipient Pulmonary Vascular Disease as an Indicator for Early PAH [Phase 2]
Phase 2 clinical trial update on the efficacy and safety of riociguat for incipient pulmonary vascular disease as an early indicator for pul…
-
CLINICAL_TRIALS trial_result · 2026-01-09Clinical Trial Update: Cardiac Assessment by PV Loop in IPAH and Scleroderma PAH
Johns Hopkins University conducted a clinical trial using PV loop cardiac assessment in patients with idiopathic pulmonary arterial hyperten…
-
CLINICAL_TRIALS research · 2025-11-19Clinical Trial Update: Multicenter Study on the Development of Pulmonary Arterial Hypertension Screening Models Based on Artificial Intelligence for Patients With Systemic Sclerosis
A multicenter clinical trial is investigating AI-based screening models for detecting pulmonary arterial hypertension in patients with syste…
-
FDA label_change · 2024-05-30FDA Approved: BOSENTAN — Supplemental Application (Zydus Pharmaceuticals USA Inc.)
FDA approved a supplemental application for Bosentan from Zydus Pharmaceuticals USA Inc. The update aligns the generic's labeling with the b…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2022-04-29FDA Approved: BOSENTAN — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approved a supplemental application for Bosentan submitted by Sun Pharmaceutical Industries, Inc. This approval expands the drug's label…
-
CLINICAL_TRIALS trial_result · 2020-08-21Clinical Trial Update: Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH) [Phase 2]
Phase 2 trial evaluating rituximab for systemic sclerosis-associated pulmonary arterial hypertension has completed; results posted in 2020.
-
CLINICAL_TRIALS research · 2017-02-15Clinical Trial Update: To Compare the Efficacy of Combination Therapy vs Monotherapy for Pulmonary Arterial Hypertension in Systemic Sclerosis [Phase 4]
A Phase 4 clinical trial is evaluating combination therapy versus monotherapy for pulmonary arterial hypertension in systemic sclerosis, wit…